Linvoseltamab is a fully human bispecific monoclonal antibody designed to target B-cell maturation antigen, known as BCMA, and CD3 expressed on T cells. By engaging BCMA-positive cells with CD3-expressing T cells, linvoseltamab facilitates T-cell activation and targeted cell killing.
Linvoseltamab is classified as a BCMA-directed CD3 T-cell engager and is associated with advanced biologic and oncology drug development. It is used in regulated pharmaceutical and biopharmaceutical applications where stringent control of identity, purity, potency, aggregates, microbial quality, and biological activity is essential.
Swapnroop Drugs and Pharmaceuticals supports pharmaceutical, research, and development requirements for specialized pharmaceutical raw materials and biologic-related sourcing. Product documentation, quality specifications, analytical requirements, and supply conditions are handled according to applicable project and customer requirements.
Linvoseltamab is associated with:
Available documentation may include, subject to product and supply requirements:
Certificate of Analysis – COA
Material Safety Data Sheet – MSDS / SDS
Product Specification Sheet
Analytical Test Report
Storage and Handling Information
Stability Information, where available
Regulatory and technical documentation, subject to agreement
Swapnroop Drugs and Pharmaceuticals is a pharmaceutical raw material supplier based in Maharashtra, India, serving pharmaceutical and research requirements.
We focus on:
Swapnroop Drugs and Pharmaceuticals supplies and supports specialized pharmaceutical raw material requirements for pharmaceutical companies, research organizations, formulation developers, and international buyers.
For Linvoseltamab API / biologic drug substance requirements, customers may contact our team for availability, specification, documentation, quantity, packaging, and commercial information.
Company Name: Swapnroop Drugs and Pharmaceuticals
Location: Maharashtra, India
Email: enquiry@sdp.org.in
Website: www.sdp.org.in